Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

Intuitive Surgical, Inc. (ISRG) reported $2.44 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 21.4%. EPS of $2.19 for the same period compares to $1.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.35 billion, representing a surprise of +3.93%. The company delivered an EPS surprise of +14.06%, with the consensus EPS estimate being $1.92.While investors scrutinize revenue and earnings changes year-over-year and how they compare w ...

Carlsmed, which uses AI to personalize spine surgery, raised $100.5 million in its IPO, pricing shares within a marketed range. https://t.co/oz19Eg4bQU ...

NDAMENTALS INVESTOR EXPERIENCE MELBOURNE Wednesday 23 July 2025 for personal use only For personal use only For personal use only For personal use only NDAMENTALS INVESTOR EXPERIENCE MELBOURNE Wednesday 23 July 2025 for personal use only Today's rotations 2 3 / personal use only Optiflow & NIV in Neonatal Optiflow on Anaesthesia the ED Care the Ward With Dr Gerben Keijzers With Dr Peter Davis With Associate Professor With Professor Reny Segal and Associate Professor Benjamin Kwan Pierre Bradley Fisher & Pay ...

Image source: The Motley Fool.Tuesday, July 22, 2025 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dave RosaChief Financial Officer — Jamie SamathChief Medical Officer — Dan ConnallyNeed a quote from one of our analysts? Email [email protected] RISKSJamie Samath stated, "pro forma gross margin was 67.9% in Q2 2025, down from 70% in Q2 2024." attributing the decline to "higher facilities costs," "a greater mix of lower-margin ION and da Vinci five revenue," and "higher service costs related to da ...

WARSAW, Ind., July 22, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2025 financial results on August 5, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 5, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call ...

EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave’s group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the presentation, ...

SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Invest ...

ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the confer ...

Tuesday, July 22, 2025Pre-market futures are inching higher once again this morning. We are devoid major economic reports ahead of today’s open, but have plenty of quarterly earnings results, as you can see below. The Dow and the S&P 500 are both currently up +9 points, while the Nasdaq is +4 points. Bond yields continue to shrink away: +4.36% on the 10-year, +3.84% on the 2-year, and it look like we’ll once again stop talking about the 30-year bond yield, which is down to +4.94%. Biggest Q2 Earnings Mornin ...